Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15831920 | 0.86 | L3MBTL1 (0.43) | L3MBTL1GAATDP1MAPTKDM4E | |
| SCHEMBL15831912 | 0.85 | GAA (0.42) | L3MBTL1GAATDP1MAPTKDM4E | |
| SCHEMBL15831906 | 0.84 | L3MBTL1 (0.42) | L3MBTL1GAATDP1MAPTKDM4E | |
| SCHEMBL15831921 | 0.83 | ALDH1A1 (0.45) | L3MBTL1GAATDP1MAPTKDM4E | |
| SCHEMBL15831951 | 0.82 | L3MBTL1 (0.40) | L3MBTL1GAATDP1MAPTKDM4E | |
| SCHEMBL15831911 | 0.82 | ALDH1A1 (0.47) | L3MBTL1GAATDP1MAPTKDM4E | |
| SCHEMBL26750091 | 0.81 | HDAC1 (0.41) | L3MBTL1GAATDP1MAPTKDM4E | |
| SCHEMBL15831917 | 0.81 | MAP3K7 (0.46) | L3MBTL1HDAC1MEN1KMT2A | |
| SCHEMBL15831942 | 0.81 | HDAC1 (0.55) | L3MBTL1GAATDP1MAPTKDM4E | |
| SCHEMBL15831949 | 0.81 | L3MBTL1 (0.45) | L3MBTL1GAATDP1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| EP-0186049-B1 | N-SUBSTITUTED AZIRIDINE-2-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AS WELL AS MEDICAMENTS CONTAINING THESE SUBSTANCES | Roche Diagnostics GmbH (DE) | 1990-07-04 | — | — | EP | disclosed |
| US-4826858-A | IMMUNO-STIMULATING AND IMMUNO-MODULATING ACTIVATIES | BOEHRINGER MANNHEIM GMBH (DE) | 1989-05-02 | — | — | US | disclosed |
| EP-0186049-A1 | N-substituted aziridine-2-carboxylic acid derivatives, process for their preparation as well as medicaments containing these substances | Roche Diagnostics GmbH (DE) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | L3MBTL1 3202/4885GAA 4839/4885TDP1 3833/4885 |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, PGM2 | L3MBTL1 828/4885GAA 9/4885TDP1 1504/4885 |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | TRPV1, TRPV5, TRPV2 | L3MBTL1 4845/4885GAA 3229/4885TDP1 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.